Chemed Remains Well-Positioned and 4 Stock Analyses Making Headlines
Lumber Liquidators Holdings, Inc. (NYSE:LL): After the 5.25 percent sell-off yesterday in Lumber Liquidators shares, causing Piper Jaffray to claim that the company’s growth story continues to be fully intact, and the firm has increased its price target to $56 from $48 on the shares. Piper still believes that the flooring market is rebounding well in 2012.
TearLab Corporation (NASDAQ:TEAR): California passed a law that enables optometrists to perform clinical lab tests within their practice. According to the firm, the law will be a long-term positive for TearLab and its osmolarity system. Shares have a Buy rating and a $6 price target.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Chemed Corp. (NYSE:CHE): Following its meetings with Chemed’s management, Oppenheimer thinks that the company’s hospice business continues to be in an ideal position, as its Roto-Rooter unit still provides solid cash flow. The firm keeps its Outperform rating and increased its target to $80 from $75 on the stock.
McMoRan Exploration Co. (NYSE:MMR): According to Susquehanna, McMoRan Exploration has added LNG export catalysts to 2013 which makes the stock seem more appealing. Additionally, the firm believes that the first flows from its Davy Jones field will have the ability to increase its negotiating leverage for upstream deals. Shares have a Positive rating and an $18 price target.
Celgene Corporation (NASDAQ:CELG) valuation range has been raised by Wells Fargo due to the firm’s expectations that Revlimid subscription trends will be positive, and it also believes that there is more probability of success for the Celgene’s apremilast program. The firm reiterates its Outperform rating on the stock.
Don’t Miss: Family Dollar Stores Earnings: Profit Rises.